Diabetic Peripheral Neuropathy

SAN DIEGO — Treatment with a spinal cord stimulation system reduced pain and restored sensory nerve function in a small cohort of individuals with diabetic peripheral neuropathy, according to a presenter.

Patients with type 2 diabetes and more severe peripheral neuropathy appeared to be at greater risk for developing dry eye disease, according to a study published in Optometry and Vision Science.

The FDA has approved an expanded indication of Boston Scientific’s spinal cord stimulation system that treats painful diabetic peripheral neuropathy, a complication of diabetes that often affects the lower extremities.

The FDA has approved the Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral neuropathy, manufacturer Abbott announced in a press release.

Diabetic peripheral neuropathy is a debilitating, progressive neurologic disorder that affects about 30% of adults with diabetes. Spinal cord stimulation is a newer option for addressing moderate to severe pain related to the condition.

The FDA approved the use of a spinal cord stimulation therapy for the treatment of chronic pain caused by diabetic peripheral neuropathy, according to a press release from Medtronic.

Diabetic peripheral neuropathy is associated with a decline in cognition for people with type 2 diabetes, according to study findings published in the Journal of Diabetes and its Complications.

Among adults with newly diagnosed diabetic peripheral neuropathy treated at a multi-campus health system, 43.8% were prescribed opioids, whereas only 42.9% were prescribed a recommended first-line pain medication, according to study data.

Adults with type 1 diabetes who have diabetic peripheral neuropathy are more likely to experience severe hypoglycemia or diabetic ketoacidosis than their peers without peripheral neuropathy, according to findings published in Diabetes Care.

Adults with type 2 diabetes may be at higher risk for major adverse cardiovascular events, coronary artery disease and other cardiometabolic disorders if they consistently experience large changes in HbA1c, according to findings published in Diabetes Care.